Sepsis Breakthrough: Acetaminophen Lowers Risk of Organ Injury 

Sepsis Breakthrough: Acetaminophen Lowers Risk of Organ Injury. Credit | AP
Sepsis Breakthrough: Acetaminophen Lowers Risk of Organ Injury. Credit | AP

United States: Another study conducted by a research team, where the National Institute of Health held the grant, and the clinical trial discovered that intravenous acetaminophen administration also decreases the likelihood of organ failure and acute respiratory distress syndrome in sepsis patients. 

These conditions help to enable fluid to enter the lungs primarily and this is dangerous to the overall health of a human being. Sepsis can be thus described as being an uncontrolled inflammation of the body in response to the infection. 

More About the Trial 

While the trial did not reduce mortality rates for all sepsis patients, scientists noted significant benefits for those experiencing organ failure. The findings, published in JAMA, indicate that patients undergoing this therapy required less assisted ventilation and experienced only minor reductions in mortality rates. 

Sepsis Breakthrough: Acetaminophen Lowers Risk of Organ Injury. Credit | Shutterstock
Sepsis Breakthrough: Acetaminophen Lowers Risk of Organ Injury. Credit | Shutterstock

With the help of therapy, the patients who required a lesser level of assisted ventilation thus went through a little and insignificant depreciation in death rate. 

In the case of sepsis, RBCs bear the injury and hence die at a very uncommonly high rate, thereby releasing “cell-free hemoglobin” into the blood. 

Previously done work from Lorraine Ware, M.D., professor of medicine, pulmonary and critical care at Vanderbilt University, Nashville, Tennessee, and who is also the first author of the current study, showcased a fact that acetaminophen in plus of relieving pain and lessening fevers, had shown ways to block the harms of cell-free hemoglobin on the lungs. 

According to Michael Matthay, M.D., professor of medicine and anesthesia at the University of California, San Francisco, and the senior study author, “One problem in critical care is the patients get sick so fast, that we do not normally have time to figure out which biomarkers help predict which therapy could give the best outcome,” Fox News reported. 

He added, “We hope that these findings will underscore the potential therapeutic value of using a biomarker to help successfully find a treatment that will work when patients need it the most.” 

Conducting the Test 

To evaluate the therapeutic potential of acetaminophen, researchers conducted a mid-stage clinical trial involving 447 adults with sepsis and respiratory or circulatory organ dysfunction across 40 US academic hospitals from October 2021 to April 2023. 

James Kiley, Ph.D., director of the Division of Lung Diseases at the National Heart, Lung, and Blood Institute, part of NIH, said, “While the anticipated effects of acetaminophen therapy were not realized for all sepsis patients, this study shows that it still holds promise for the most critically ill,” as Fox News reported. 

He said, “Though, more research is needed to uncover the mechanisms and validate these results.”